AU8828798A - Dairy products with enhanced cla content - Google Patents
Dairy products with enhanced cla content Download PDFInfo
- Publication number
- AU8828798A AU8828798A AU88287/98A AU8828798A AU8828798A AU 8828798 A AU8828798 A AU 8828798A AU 88287/98 A AU88287/98 A AU 88287/98A AU 8828798 A AU8828798 A AU 8828798A AU 8828798 A AU8828798 A AU 8828798A
- Authority
- AU
- Australia
- Prior art keywords
- milk
- fat
- fatty acid
- dairy product
- cla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013365 dairy product Nutrition 0.000 title claims description 78
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 86
- 229930195729 fatty acid Natural products 0.000 claims description 86
- 239000000194 fatty acid Substances 0.000 claims description 86
- 150000004665 fatty acids Chemical class 0.000 claims description 82
- 235000013336 milk Nutrition 0.000 claims description 81
- 239000008267 milk Substances 0.000 claims description 81
- 210000004080 milk Anatomy 0.000 claims description 81
- 235000019197 fats Nutrition 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 61
- 235000021323 fish oil Nutrition 0.000 claims description 57
- 235000005911 diet Nutrition 0.000 claims description 48
- 241000283690 Bos taurus Species 0.000 claims description 45
- 230000037213 diet Effects 0.000 claims description 44
- 235000021243 milk fat Nutrition 0.000 claims description 41
- 241000282849 Ruminantia Species 0.000 claims description 26
- 239000003921 oil Substances 0.000 claims description 26
- 235000019198 oils Nutrition 0.000 claims description 26
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 21
- 235000020185 raw untreated milk Nutrition 0.000 claims description 20
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 19
- CNVZJPUDSLNTQU-SEYXRHQNSA-N petroselinic acid Chemical compound CCCCCCCCCCC\C=C/CCCCC(O)=O CNVZJPUDSLNTQU-SEYXRHQNSA-N 0.000 claims description 19
- 235000014121 butter Nutrition 0.000 claims description 18
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 238000002844 melting Methods 0.000 claims description 12
- OXEDXHIBHVMDST-UHFFFAOYSA-N 12Z-octadecenoic acid Natural products CCCCCC=CCCCCCCCCCCC(O)=O OXEDXHIBHVMDST-UHFFFAOYSA-N 0.000 claims description 11
- 241000273930 Brevoortia tyrannus Species 0.000 claims description 10
- CNVZJPUDSLNTQU-UHFFFAOYSA-N Petroselaidic acid Natural products CCCCCCCCCCCC=CCCCCC(O)=O CNVZJPUDSLNTQU-UHFFFAOYSA-N 0.000 claims description 9
- AQWHMKSIVLSRNY-UHFFFAOYSA-N trans-Octadec-5-ensaeure Natural products CCCCCCCCCCCCC=CCCCC(O)=O AQWHMKSIVLSRNY-UHFFFAOYSA-N 0.000 claims description 9
- 230000008018 melting Effects 0.000 claims description 8
- 235000015155 buttermilk Nutrition 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 7
- 235000013618 yogurt Nutrition 0.000 claims description 7
- 241000283707 Capra Species 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 5
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 5
- 235000013351 cheese Nutrition 0.000 claims description 5
- 241000282994 Cervidae Species 0.000 claims description 4
- 239000005862 Whey Substances 0.000 claims description 4
- 102000007544 Whey Proteins Human genes 0.000 claims description 4
- 108010046377 Whey Proteins Proteins 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 4
- 235000020186 condensed milk Nutrition 0.000 claims description 4
- 235000015142 cultured sour cream Nutrition 0.000 claims description 4
- 235000013367 dietary fats Nutrition 0.000 claims description 4
- 235000020187 evaporated milk Nutrition 0.000 claims description 4
- 239000010520 ghee Substances 0.000 claims description 4
- 235000015243 ice cream Nutrition 0.000 claims description 4
- 229960004488 linolenic acid Drugs 0.000 claims description 4
- 235000008476 powdered milk Nutrition 0.000 claims description 4
- 235000012716 cod liver oil Nutrition 0.000 claims description 3
- 239000003026 cod liver oil Substances 0.000 claims description 3
- 241000252203 Clupea harengus Species 0.000 claims description 2
- 241000269821 Scombridae Species 0.000 claims description 2
- 241001233037 catfish Species 0.000 claims description 2
- 235000019514 herring Nutrition 0.000 claims description 2
- 235000020640 mackerel Nutrition 0.000 claims description 2
- 229940119224 salmon oil Drugs 0.000 claims description 2
- 239000003925 fat Substances 0.000 description 58
- 239000000047 product Substances 0.000 description 36
- 238000000034 method Methods 0.000 description 28
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 27
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 27
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 16
- 235000019733 Fish meal Nutrition 0.000 description 15
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 15
- 239000004467 fishmeal Substances 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 230000009286 beneficial effect Effects 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 241000251468 Actinopterygii Species 0.000 description 11
- 235000019688 fish Nutrition 0.000 description 11
- 150000003626 triacylglycerols Chemical class 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 231100000504 carcinogenesis Toxicity 0.000 description 10
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 208000005623 Carcinogenesis Diseases 0.000 description 9
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 9
- 241000030538 Thecla Species 0.000 description 9
- 230000036952 cancer formation Effects 0.000 description 9
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 9
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 8
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 8
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 8
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 8
- -1 fatty acid salt Chemical class 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 235000019165 vitamin E Nutrition 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 7
- 239000006014 omega-3 oil Substances 0.000 description 7
- 235000003441 saturated fatty acids Nutrition 0.000 description 7
- 150000004671 saturated fatty acids Chemical class 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 229940090949 docosahexaenoic acid Drugs 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 235000020778 linoleic acid Nutrition 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000007670 refining Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 4
- 235000019738 Limestone Nutrition 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 235000019764 Soybean Meal Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940108924 conjugated linoleic acid Drugs 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 4
- 229940038472 dicalcium phosphate Drugs 0.000 description 4
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000006028 limestone Substances 0.000 description 4
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000395 magnesium oxide Substances 0.000 description 4
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 4
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 4
- 239000004455 soybean meal Substances 0.000 description 4
- 235000012424 soybean oil Nutrition 0.000 description 4
- 239000003549 soybean oil Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 description 4
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 3
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 239000004459 forage Substances 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 150000004668 long chain fatty acids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 235000014059 processed cheese Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000000194 supercritical-fluid extraction Methods 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000004658 Medicago sativa Species 0.000 description 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003043 biohydrogenation Effects 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940088033 calan Drugs 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 235000006486 human diet Nutrition 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000944 linseed oil Substances 0.000 description 2
- 235000021388 linseed oil Nutrition 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 230000023247 mammary gland development Effects 0.000 description 2
- 235000016046 other dairy product Nutrition 0.000 description 2
- CNVZJPUDSLNTQU-OUKQBFOZSA-N petroselaidic acid Chemical compound CCCCCCCCCCC\C=C\CCCCC(O)=O CNVZJPUDSLNTQU-OUKQBFOZSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000004767 rumen Anatomy 0.000 description 2
- 239000004460 silage Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- ZUUFLXSNVWQOJW-MBIXAETLSA-N (2e,4e,6e)-octadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C(O)=O ZUUFLXSNVWQOJW-MBIXAETLSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 239000001195 (9Z,12Z,15Z)-octadeca-9,12,15-trienoic acid Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000944683 Bandara Species 0.000 description 1
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- FXVQIAPSJGBLJJ-UHFFFAOYSA-N butan-1-ol;trifluoroborane Chemical compound FB(F)F.CCCCO FXVQIAPSJGBLJJ-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 238000003965 capillary gas chromatography Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000020667 long-chain omega-3 fatty acid Nutrition 0.000 description 1
- 235000020121 low-fat milk Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000010461 other edible oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000007248 oxidative elimination reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
Landscapes
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Birds (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Dairy Products (AREA)
Description
WO 99/08540 PCT/US98/16829 DAIRY PRODUCTS WITH ENHANCED CLA CONTENT Background of the Invention Conjugated linoleic acids ("CLA") are a group of octadecadienoic acids with conjugated double bonds that has been shown to have anticarcinogenic properties 5 (see, e.g., Ha et al., Cancer Res., 50:1097 (1990); Ip et al., Cancer Res., 51:6118 (1991); Ip et al., Carcinogenesis, 17:1045 (1996)). Conjugated linoleic acids are found primarily in meat (Ha et al., Carcinogenesis, 8:1881 (1987); Pariza et al., Carcinogenesis, 6:591 (1985)) and dairy products from ruminant animals (Ha et al., J. Agric. Food Chem., 37:75 (1989); Lin et al., J. Dairy Sci., 78:2358 (1995)). The 10 collective term, CLA, incorporates several isomers, with double bonds present at positions 9 and 11, or 10 and 12, or 11 and 13 on the carbon chain of octadecadienoic acid. The double bond at each of the positions can be in the cis- or trans- form (Parodi, Aust. J. Dairy Technol., 49:93 (1994)). The cis-9, trans-11I octadecadienoic acid isomer is considered by some to be the most potent 15 anticarcinogen (see Ha et al., Cancer Res., 50:1097 (1990); Ip et al., Cancer Res., 51:6118 (1991)). Several studies have provided increasing evidence that CLA is inhibitory toward cancer. Mice fed a diet containing a synthetic form of CLA and subjected to cancer initiation treatments developed 50% fewer forestomach tumors than mice fed 20 control diets (Ha et al., Cancer Res., 50, 1097 (1990)). Rats fed diets supplemented with 0.5, 1, or 1.5% synthetic CLA and subjected to carcinogens developed 32, 56, and 60% fewer mammary adenocarcinomas, respectively, than rats fed control diets (Ip et al., Cancer Res., 51, 6118 (1991)). Another study by Ip et al. (Carcinogenesis, 17, 1045 (1996)) reported that addition of CLA to the diet inhibited mammary 25 tumorigenesis regardless of the level or type of fat in the diet. Also, female rats fed CLA during mammary gland development exhibited approximately 35% fewer tumors than rats fed control diets even though all rats were fed the control diet after carcinogen treatment (Ip et al., Cancer Res., 54:1212 (1994)). These results provide strong evidence that CLA can help decrease the incidence of cancer and suggest that 30 CLA intake during mammary gland development may provide lasting protection against subsequent mammary tumorigenesis. 1 WO 99/08540 PCT/US98/16829 The amount of CLA humans should consume to provide protection against cancer is not currently known. Studies with rats indicated that 1% of the diet as CLA resulted in maximal inhibition of tumorigenesis. A subsequent study (Ip et al., Cancer Res., 54, 1212 (1994)) reported that as little as 0.1% CLA in the diet of rats 5 inhibited tumorigenesis. Parodi (Aust. J. Dairy Technol., 49:43 (1994)) suggested that Australians may normally consume from 0.5 to 1.5 g of CLA per day which would be equivalent to approximately 0.05 to 0.15 % of the diet, a level shown to cause inhibition of tumorigenesis in rats. Assuming the average CLA content of milk fat is approximately 3 mg/g, increasing the CLA content 10 fold to 30 mg/g 10 would provide approximately the 1% level of CLA in the diet which, in rats, provided maximal inhibition of cancer. Dairy products are an important source in human diets of naturally occuring CLA. Dairy products typically contain from 2.5 to 7.0 mg CLA/g of fat (Lin et al., J. Dairy Sci., 78:2358 (1995)). Research reported by Riel indicated the total 15 conjugated diene content of milk fat can vary from 0.78 to 1.46% (or approximately 8 to 15 mg/g) of fat depending on season (J. Dairy Sci., 46:102 (1963)). Riel found that cows consuming pasture during the spring have increased amounts (to 1.46%) of conjugated dienoic acid in the milk fat. In contrast, however, Mackle et al. (J. Dairy Sci., 80 (Suppl. 1):154 (1997)) reported little variation in CLA content with 20 season or type of pasture. It has been speculated that the cis-9, trans-11 octadecadienoic acid is produced in the rumen as a first intermediate in the biohydrogenation of linoleic acid by linoleic acid isomerase from Butyrivibrio fibrisolvens. (see, e.g., Kepler et al., J. Biol. Chem., 241:1350 (1996)). It is believed that differing CLA contents of various dairy products probably do not 25 represent different milk processing conditions, but are most likely due to fluctuating levels of CLA in raw milk. Ruminal biohydrogenation of dietary long-chain fatty acids also may result in production of trans C 18:1 fatty acids which can be incorporated in milk fat (see, e.g., Loor et al., J. Dairy Sci., 80(Suppl. 1):164 (1997); Piperova et al., J. Dairy Sci., 30 80(Suppl. 1):164 (1997); Wonsil et al., J. Nutr., 124:556 (1994)). Dairy products typically contain low concentrations of trans C 18:1 fatty acids, therefore, few studies have investigated specific trans C 18:1 fatty acids. Transvaccenic acid [trans 2 WO 99/08540 PCT/US98/16829 18:1 (n-7)] has been shown to inhibit growth of colonic cancer cells in vitro (Awad et al., Cancer Letters, 91:55 (1995)) and decrease fat accumulation in rat adipocytes (Cromer et al., J. Nutr., 125:2394 (1995)). Increased transvaccenic acid in dairy products may have important health benefits for humans. Another C 18:1 fatty acid, 5 petroselinic acid, may also be a beneficial fatty acid in human diets. Petroselenic acid [18:1 (n- 12)] has been shown to decrease the concentration of arachidonic acid in lipids from heart, liver, and blood (Weber et al., J. Nutr., 125:1563 (1995)). Omega-3 fatty acids also have been shown to provide important health benefits. Two omega-3 fatty acids, eicosapentaenoic acid ("EPA", C20:5) and 10 docosahexaenoic acid ("DHA", C22:6) have been shown to have beneficial effects on human cardiovascular disease (see, e.g., Bang et al., Acta Med. Scand., 200:69 (1976); Hirai et al., Lancet, 2(8204):1132-33 (1976)), rheumatoid arthritis (Kremer et al., Ann. Intern. Med., 104:497 (1987)), dermatitis (Bjornobe et al., Brit. J. Dermatol., 117:463 (1987)), and ulcerative colitis (Ross, Nutr. Rev., 51:47 (1993)). 15 Additionally, intake of omega-3 fatty acids has been linked to inhibition of prostate cancer (Rose et al., Lipids, 27:798 (1992)) and pancreatic cancer (Roebuck, Lipids, 27:804 (1992)). Human dietary sources of long-chain omega-3 fatty acids are generally limited to some cold water, deep sea fish and a few plant sources. Incorporation of omega-3 fatty acids into a widely available and palatable form of 20 food, such as dairy products, would provide greater access to omega-3 fatty acids at a reasonable price. The fat fraction of milk from ruminant animals contains numerous fatty acids, mainly saturated (circa 66%), but also monounsaturated (circa 30%) and polyunsaturated (circa 4%). All short-chain (C4:0 to C 10:0) and half of the 25 medium-chain (C12:0 to C17:0) fatty acids in milk fat are synthesized from acetate and B-hydroxybutyrate in the mammary gland epithelial cells. The other half of medium-chain and almost all long-chain (C18:0 and longer) fatty acids are derived from blood plasma fatty acids of dietary origin as modified by rumen microbial fermentation or from mobilization of body fat stores. 30 Several attempts have been made to increase the CLA content of milk fat by feeding diets high in linoleic and linolenic acids. In one report, cows were fed diets containing raw soybeans, roasted soybeans, soybean oil, 2.2% linseed oil, or 4.4% 3 WO 99/08540 PCT/US98/16829 linseed oil and it was reported that milk fat from cows fed soybean oil contained an average of 21.2 mg CLA/g of fat (Dhiman et al., J. Dairy Sci., 80(Suppl. 1):184 (1997)). In a subsequently conducted study feeding several levels of soybean oil, it was reported a concentration of 20.8 mg CLA/g of fat was achieved with 4% 5 soybean oil. Loor et al. found only minor increases (5 mg/g of fat vs. 2.3 mg/g of fat) in CLA when cows were fed canola oil or canolamide compared to control cows (Loor et al., J. Dairy Sci., 80(Suppl. 1):164 (1997)). Similarly, no differences in CLA content of milk fat was observed when cows were fed canola oil, olive oil, or high-oleic sunflower oil compared to control diets (Bandara et al, J. Dairy Sci., 10 80(Suppl. 1):242 (1997)). Kelly et al., however, reported concentrations of CLA averaged 18.1 mg/g of fat when cows were fed sunflower oil high in linolenic acid (Kelly et al., J. Dairy Sci., 80(Suppl. 1):243 (1997)). Other studies have addressed alterations in CLA concentrations as influenced by forage to concentrate ratios, season, or pasture feeding. Jiang et al. reported that 15 cows fed a ration containing 35:65 forage to concentrate ratio had CLA contents in milk fat averaging 11.28 mg/g of fat compared to 5.05 mg CLA/g of fat for cows fed a 50:50 forage to concentrate ration (Jiang et al., J. Dairy Sci., 79:438 (1997)). Mackle et al. (1997, supra) investigated effects of season and pasture feeding on CLA concentrations and found little variation in CLA content as a result of season or 20 type of pasture. Loor et al (1997, supra) reported the content of CLA in milk fat could be increased as a result of abomasal infusion of CLA and the content of CLA in milk fat was directly related to the amount of CLA available in the small intestine. Fish oil and fish meal have been included in diets for dairy cows as sources of energy (see, e.g., Jones et al., J. Dairy Sci., 80(Suppl. 1):243 (1997)) and bypass 25 protein (see, e.g., Calsamiglia et al., J. Dairy Sci., 78:1999 (1995); and Windschitl, J. Dairy Sci., 74:3475 (1991)). Other studies have investigated effects of feeding fish meal and fish oil on milk fat depression (see, e.g., Pennington et al., J. Dairy Sci., 58:49 (1975); and Spain et al, J. Dairy Sci., 78:1142 (1995)). Pennington et al. (1975, supra) reported increases in trans monounsaturated fatty acids in milk fat as a 30 result of feeding cod-liver oil but did not characterize individual C 18:1 isomers and did not measure CLA. Fish oil has also been included in rations of dairy cows in an attempt to alter the degree of unsaturation of milk fat (Brumby et al., J. Dairy Res., 4 WO 99/08540 PCT/US98/16829 39:167 (1972); Storry et al., J. Dairy Sci., 57:1046 (1974)). Although several studies have examined effects of feeding fish oil and fish meal on milk composition as a part of the effects of feeding these products as energy and protein sources, no previous studies have investigated the effects of feeding fish-derived materials, such 5 as fish oil or fish meal, on CLA content of milk and dairy products. Summary of the Invention The invention relates to dairy products enriched in conjugated linoleic acids ("CLA") and other beneficial unsaturated fatty acids. The dairy product typically 10 has a fat fraction with a fatty acid composition which includes at least about 15 mg/g CLA, as well as other beneficial fatty acids such as transvaccenic acid, petroselinic acid and omega-3 fatty acid(s). Milk with this unsaturated fatty acid content may be produced by a ruminant which has been fed a diet which includes a fish-derived product such as fish oil or fish meal. The diet typically includes about 0.25% to 15 about 10% by dry weight of oil supplied by the fish-derived product. The ruminant is an animal such as a cow, sheep, buffalo or goat. Examples of dairy products of the present invention include milk in raw or processed form and other products derived from the milk. The processed milk may be in a variety of forms, e.g., reduced and low fat forms, such as "1% milk," or enriched fat forms, such as cream 20 or "half and half." Other examples of the present dairy products include products obtained by further processing of the milk, such as natural and processed cheeses, cottage cheese, yogurt, butter, ice cream, butter milk, cultured butter milk, sour cream, ghee, frozen yogurt, sherbet, anhydrous butter oil, anhydrous butter fat, powdered milk, condensed milk, evaporated milk and whey products. 25 For example, the unsaturated fatty acid-enriched milk may be produced by feeding a lactating ruminant animal a diet which includes fish oil at about 0.5% to about 5% by dry weight of the total diet. Typically, the diet is supplemented with about 1% to about 4% by dry weight fish oil. In the method of the invention, milk is collected from the ruminant fed the fish-derived product. The milk can be used as 30 collected ("raw milk") or may be further processed into another dairy product using standard methods. The milk or other dairy product produced by the method of the invention has an enhanced level of CLA relative to milk produced by ruminants fed 5 WO 99/08540 PCT/US98/16829 a diet not supplemented with such an oil source. Preferably, the dairy product includes a fat fraction with a fatty acid composition which includes at least about 20 mg/g and more preferably, at least about 25 mg/g CLA. In other preferred embodiments of the invention, the dairy product has a fat fraction which contains 5 enhanced levels of unsaturated fatty acids such as omega-3 fatty acid(s), transvacennic acid, and/or petroselinic acid. The present invention also provides isolated lipid fractions and fatty acid compositions derived from the unsaturated fatty acid-enriched raw milk. The lipid portion can be separated from the raw milk using conventional methods, e.g., 10 supercritical fluid extraction or extraction with organic solvent. The lipid composition obtained in this manner typically has a fatty acid composition which includes at least about 20 mg/g CLA and at least about 10 mg/g omega-3 fatty acid(s). Substantial amounts of triglycerides including transvaccenic acid and petroselinic acid esters are also generally present. If desired, the lipid composition 15 derived from the raw milk (or a process version of the raw milk or lipid composition) may be hydrolysed to convert the triglycerides to free fatty acids or simple corresponding esters (e.g., "lower alkyl" esters - (C(1)-C(6) alkyl esters) of the fatty acids. Alternatively, the triglycerides may be initially converted to free fatty acids which are subsequently esterified. The products of the hydrolysis 20 reaction may be isolated in free acid form or as a salt of the fatty acid(s). The fatty acid salt(s) generally include one or more water soluble monovalent cations as the counterion, e.g., potassium (K'), sodium (Nay) and/or ammonium (NH 4 +). Either the lipid composition or the isolated fatty acids (or their corresponding esters) may be further processed to obtain various fractions based on boiling point, melting point, 25 solubility, fractional crystallization or other similar properties. Detailed Description of the Invention Definitions As used herein, "dairy product" includes milk in raw and processed form, 30 natural and processed cheeses, cottage cheese, yogurt, butter, ice cream, butter milk, cultured butter milk, sour cream, ghee, frozen yogurt, sherbet, anhydrous butter oil, anyhdrous butter fat, powdered milk, condensed milk, evaporated milk, whey 6 WO 99/08540 PCT/US98/16829 products and other milk-based products. The term "dairy product" includes any of the above product having at least about 0.5 wt.% fat content. As used herein, the terms "raw milk" and "milk produced by a ruminant animal" means isolated milk in the form directly produced by the ruminant without 5 any further processing. As used herein, the term "milk product" means any product having a fat content of at least about 0.5 wt. % derived from the raw milk by a process which does not alter its liquid state or substantially change the fatty acid composition of the fat fraction. Thus, the term "milk product" includes both raw milk as well as milk 10 which has been processed to enhance its shelf life (e.g., via pasteurization), to alter its physical consistency (e.g., via homogenization), and/or to alter the overall fat content (e.g., via separation). Examples of milk products having an altered overall fat content include enriched fat, full fat, low fat milk (e.g., 1% milk), reduced fat (e.g., 2% milk), half and half, and cream, as well as flavored milk products. 15 For purposes of definition throughout the application, it is understood herein that a fatty acid is an aliphatic (saturated or unsaturated) monocarboxylic acid. Lipids are understood to be fats or oils including the glyceride esters of fatty acids along with associated phosphatides, sterols, and related compounds. A commonly employed shorthand system is used in this specification to denote the structure of the 20 fatty acids. This system uses the letter "C" accompanied by a number denoting the number of carbons in the hydrocarbon chain, followed by a colon and a number indicating the number of double bonds,e.g., C20:5, eicosapentaenoic acid. Fatty acids are numbered starting at the carboxy carbon. The position of the double bonds may be indicated by adding the Greek letter delta (A) followed by the carbon 25 number of the double bond; e.g., C20:5omega-3A 5 ,8, 1, 4, 17 . The "omega" notation is a shorthand system for unsaturated fatty acids whereby numbering from the CH 3 terminal carbon is used. For convenience, w3 may be used to symbolize "omega-3," when using the numeral shorthand nomenclature described herein. Omega-3 highly unsaturated fatty acids are understood to be polyethylenically unsaturated fatty acids 30 in which the last ethylenic bond is between the third and fourth carbons from the
CH
3 end of the fatty acid. Thus, the complete nomenclature for eicosapentaenoic acid, a highly unsaturated omega-3 fatty acid, would be 7 WO 99/08540 PCT/US98/16829 C20:5A 5
'
8
'
11 1 4
'
17 . For the sake of brevity, the double bond locations (A 5
'
8 1 1
,'
14, 17 ) will be omitted. Eicosapentaenoic acid is then designated C20:5w3 (also referred to herein as "C20:5"), docosapentaenoic acid (C22:5A7, 1 1
,
13 1 6 19 ) is C22:5w3 (also referred to herein as "C22:5"), and docosahexaenoic acid (C22:6A4,7,10, 13
,
16 19 ) is 5 C22:6w3 (also referred to herein as "C22:6"). As used herein, the nomenclature "highly unsaturated fatty acid" ("HUFA") means a fatty acid with 4 or more double bonds. As used herein, "conjugated linoleic acid" or "CLA" means a fatty acid that is an octadecadienoic acid having conjugated double bonds at positions 9 and 11, 10 10 and 12, or 11 and 13 on the carbon chain of linoleic acid, wherein the double bond at each of these positions can be in either the cis or trans configuration. The term CLA as used herein refers to a fatty acid composition made up of one or more of the "conjugated linoleic acid" isomers. As used herein, "omega-3 fatty acid" refers to a fatty acid having a double 15 bond between the third and fourth carbons from the end of the aliphatic chain of the fatty acid. Examples of omega-3 fatty acids include ac-linolenic ("C18:3a"), eicosapentaenoic acid (a C20:5 fatty acid) and docosahexaenoic acid ("DHA"; a C22:6 fatty acid). As used herein, "ruminant" includes a cow, goat, sheep, buffalo, deer or 20 other member of the Ruminantia suborder of hooved mammals. Components of Fats and Oils Fat is made up of triacylglycerol molecules (sometimes termed triglycerides). In general, triacylglycerols comprise three long fatty acid chains esterified to 25 glycerol; or, alternatively phrased, glycerol esterified by addition thereto of three long chain fatty acids. Herein, the terms "triacylglycerols" and "triglycerides" are intended to be interchangeable. In general, fats and oils derived from any given plant or animal source comprise a mixture of triacylglycerols, characteristic of the specific source. The mixture of fatty acids isolated from complete hydrolysis of the 30 triacylglycerols in a specific fat or oil are generally referred to as a "fatty acid composition". By the term "fatty acid composition" reference is made to the identifiable fatty acid residues in the various triacylglycerols. The distribution of 8 WO 99/08540 PCT/US98/16829 specific identifiable fatty acids is typically characterized by the amounts of the individual fatty acids relative to the total mixture of fatty acids obtained from hydrolysis of the particular oil stock. Herein, the amount of an individual fatty acid is stated as the amount in milligrams (mg) of the butyl ester of the specified fatty 5 acid relative to the total weight in grams (g) of the butyl esters of all the fatty acids in the fatty acid composition. Alternatively, the amount of a fatty acid may be stated as mg of the fatty acid per gram of total fat. For example, typical fatty acid compositions of fish oil are as shown in Table 1 below. The generic fish oil shown in Table 1 was purchased from a 10 pharmacy; the Menhaden fish oil was obtained from Zapata Protein, Inc. (Reedville, VA). Palmitic (C16:0) and stearic (C18:0) acids are saturated fatty acids and triacylglycerol acyl chains formed by the esterification of either of these acids do not contain any double carbon-carbon bonds. However, many fatty acids such as oleic 15 acid (a C 18:1 fatty acid), linoleic acid (a C 18:2 fatty acid), and linolenic acid (a C18:3 fatty acid), are unsaturated. Oleic acid is an 18 carbon fatty acid with a single double bond; linoleic acid is an 18 carbon fatty acid with two double bonds or points of unsaturation; and linolenic is an 18 carbon fatty acid with three double bonds. More specifically, 20 oleic acid is (Z)-9-octadecanoic acid; linoleic acid is (Z,Z)-9,12-octadecadienoic acid; a-linolenic acid is (Z,Z,Z)-9,12,15-octadecatrienoic acid (C 18:3ca); and y-linolenic acid is the (Z,Z,Z)-6,9,12 isomer of octadecatrienoic acid (C1 8
:
3 y). 25 The present dairy products typically also contain other unsaturated fatty acids such as transvaccenic acid, petroselenic acid and/or other omega-3 fatty acid(s). Dairy Products of the Invention The invention provides a dairy product enriched in one or more conjugated 30 linoleic acids (collectively refered to as "CLA") and/or other beneficial unsaturated fatty acids. The dairy product typically has a fat fraction with a fatty acid composition which includes at least about 15 mg/g CLA. Preferably, the CLA 9 WO 99/08540 PCT/US98/16829 content of the dairy product is at least about 20 mg/gram of fat and, more preferably, at least about 25 mg/gram of fat. The dairy product may be produced by a ruminant which has been fed a diet which includes a fish-derived product such as fish oil or fish meal. Preferably, the 5 diet comprises no more than about 10% by dry weight and more preferably less than about 5% by dry weight of oil supplied by the fish-derived product. Most preferably, the diet comprises about 1% to about 4% by dry weight of a fish oil. Examples of fish oil include, but are not limited to, Menhaden fish oil, cod liver oil, mackerel oil, salmon oil, catfish oil, herring oil, sardine oil or whale oil. 10 The ruminant is an animal such as a cow, sheep, buffalo, deer or goat. The ruminant is typically fed the diet including a fish-derived product for at least about two days and, preferably, for at least about one week prior to collection of the milk produced. In addition to being enriched in CLA, milk produced by a ruminant fed a diet 15 including a fish-derived product such as fish oil may also be enriched in omega-3 fatty acids, such as a-linolenic acid (C18:3x), eicosapentaenoic acid ("EPA"; C20:5) and docosahexaenoic acid ("DHA"; C22:6). The milk typically has a fatty acid composition which includes at least about 10 mg/g omega-3 fatty acid(s). Preferably, the omega-3 fatty acid composition includes at least about 8 mg/g a 20 linolenic acid, at least about 2 mg/g eicosapentaenoic acid, and/or at least about 0.5 mg/g docosahexaenoic acid. More preferably, the omega-3 fatty acid composition includes at least about 12 mg/g a-linolenic acid, at least about 4 mg/g eicosapentaenoic acid, at least about 0.8 mg/g docosahexaenoic acid or any combination thereof. 25 The dairy product of the invention can be enriched in other fatty acids such as C18:3y, transvaccenic acid and/or petroselinic acid. Typically, the fatty acid composition includes at least about 3 mg/g C1 8
:
3 y, at least about 25 mg/g transvaccenic acid, at least about 8 mg/g petroselinic acid, or any combination thereof. Preferably, the fatty acid composition includes at least about 50 mg/g 30 transvaccenic acid together with a variety of other unsaturated fatty acids. Examples of dairy products of the present invention include milk in raw or processed form and other products derived from the milk. The milk may be 10 WO 99/08540 PCT/US98/16829 processed into a variety of forms, e.g., reduced fat such as "2% milk" or enriched fat forms such as cream and "half and half." Other examples of the present dairy products include products obtained by further processing of the milk, such as natural and processed cheeses, cottage cheese, yogurt, butter, ice cream, butter milk, 5 cultured butter milk, sour cream, ghee, frozen yogurt, sherbet, anhydrous butter oil, anyhdrous butter fat, powdered milk, condensed milk, evaporated milk and whey products. Methods of the Invention 10 The CLA-enriched milk is produced by feeding a lactating ruminant animal a diet which includes a fish-derived product such as fish oil or fish meal. For example, the diet may include fish oil as about 0.25% to about 10% by dry weight of the total diet. Typically, the diet is supplemented with about 0.5% to about 5% by dry weight of the fish oil (as a percentage of the total diet). Preferably, the fish oil is 15 no more than about 4% by dry weight of the total diet. In the method of the invention, milk is collected from the ruminant fed the fish-derived product. The milk can be used as collected, and may be further processed into another dairy product using standard methods. The milk or other dairy product produced by the method of the invention 20 includes an enhanced level of CLA relative to milk produced by ruminants fed a diet not supplemented with an oil source. Preferably, the CLA content of the dairy product is at least about 20 mg/gram of fat and, more preferably, at least about 25 mg/gram of fat. In one embodiment, the ruminant is fed the diet for at least about one week. 25 In another embodiment, the ruminant is fed the diet for at least about one day. Examples of ruminants for use in method of the invention include, but are not limited to, a cow, deer, goat, buffalo or sheep. Highly unsaturated fatty acids ("HUFAs"), such as those produced by the present process, when exposed to oxidizing conditions can be converted to less 30 desirable unsaturated fatty acids or to saturated fatty acids. Saturation of omega-3 HUFAs can be reduced or prevented by the introduction of synthetic antioxidants or 11 WO 99/08540 PCT/US98/16829 naturally occurring antioxidants, such as beta-carotene, vitamin E and vitamin C, into the dairy products. Synthetic antioxidants, such as butylated hydroxytoluene ("BHT"), butylated hydroxyanisole ("BHA"), t-butylhydroquinone ("TBHQ"), and ethoxyquin, or 5 natural antioxidants such as tocopherols, can be incorporated into the dairy products or food or feed products derived therefrom by adding them to the products during processing. The amount of antioxidants incorporated in this manner depends, for example, on subsequent use requirements, such as product formulation, packaging methods, and desired shelf life. Alternatively, compounds which act synergistically 10 with antioxidants to prevent oxidation (e.g., ascorbic acid, citric acid, phosphoric acid) can also be added. Lipids containing the CLA and other beneficial unsaturated fatty acids can also be extracted from the milk products by any suitable means, such as by supercritical fluid extraction, or by extraction with solvents such as chloroform, 15 hexane, methylene chloride, methanol, and the like, and the extract evaporated under reduced pressure to produce a sample of concentrated lipid material. The CLA and other beneficial unsaturated fatty acids in this preparation may be further concentrated by hydrolyzing the lipids and concentrating the unsaturated fraction by employing traditional methods such as urea adduction, fractional distillation or 20 column fractionation. The lipids can also be extracted from the milk products into vegetable or other edible oil. The extracted oils can be refined by well-known processes routinely employed to refine vegetable oils (e.g., chemical refining or physical refining). These refining processes can remove impurities from extracted oils before they are used or sold as edible oils. The refining process consists of a 25 series of processes to degum, bleach, filter, deodorize and polish the extracted oils. Alternatively, vegetable oil which has already been subjected to one or more of these refining processes can be used as the extractant. After refining, the oils can be used directly as a feed or food additive to produce products enriched in CLA and other beneficial unsaturated fatty acids. Alternatively, the oil can be further processed and 30 purified as outlined below and then used in the above applications and also in pharmaceutical applications. 12 WO 99/08540 PCT/US98/16829 The lipids from the obtained milk products may be extracted by use of a solvent or mixture of solvents such as hexane, chloroform, ether, or methanol. The solvent is removed (for example by a vacuum rotary evaporator, which allows the solvent to be recovered and reused) and the resulting lipid fraction can be 5 hydrolyzed by using any of the well-known methods for converting triglycerides to free fatty acids or esters of fatty acids including base hydrolysis, acid hydrolysis, or enzymatic hydrolysis. The hydrolysis is preferably carried out at as low a temperature as possible (e.g., room temperature to 60 0 C) and under nitrogen to minimize degradation of the unsaturated fatty acids. After hydrolysis is completed, 10 nonsaponifiable compounds can be extracted into a solvent such as ether, hexane or chloroform and removed. The remaining solution is then acidified by addition of an acid such as HCI and the free fatty acids can be extracted into a solvent such as hexane, ether, or chloroform. The solvent solution containing the free fatty acids could then be cooled to a temperature low enough for the non-HUFAs to crystallize, 15 but not so low that HUFAs crystallize. For example, the solution may be cooled to between about -60oC and about -74oC. The crystallized fatty acids (saturated fatty acids, and mono-, di-, and tri-enoic fatty acids) can then be removed (while keeping the solution cooled) by filtration, centrifugation or settling. The HUFAs remain typically dissolved in the filtrate (or supernatant). The solvent in the filtrate (or 20 supernatant) can then be removed leaving a mixture of fatty acids which are > 90% purity in either omega-3 HUFAs or HUFAs which are greater than or equal to 20 carbons in length. The purified highly unsaturated fatty acids can then be used as a nutritional supplement for humans, as a food additive, or for pharmaceutical applications. For these uses the purified fatty acids can be encapsulated or used 25 directly. Antioxidants are typically added to the fatty acids to improve their stability. As discussed in detail above, the milk product (or a dry form thereof) can be used directly as a food additive to enhance the content of CLA and other beneficial unsaturated fatty acids of processed foods for human intake or for animal feed. 30 When used as animal feed supplement, CLA and other beneficial unsaturated fatty acids from the present dairy products may be incorporated into the flesh or other products of animals. 13 WO 99/08540 PCT/US98/16829 The complex lipids containing CLA and other beneficial unsaturated fatty acids can also be extracted from the milk product with solvents and utilized in a more concentrated form (e.g., encapsulated) for pharmaceutical or nutritional purposes and industrial applications. A further aspect of the present invention 5 includes introducing CLA and other beneficial unsaturated fatty acids from the foregoing sources into humans for the treatment of various diseases. As defined herein, "treat" means both the remedial and preventative practice of medicine. The dietary value of CLA and other beneficial unsaturated fatty acids is recognized in the literature as decribed herein, and intake of CLA and other beneficial unsaturated 10 fatty acids produced in accordance with the present invention by humans can be effective for treating cardiovascular diseases, inflammatory and/or immunological diseases and cancer. Fractionating Milk Fat Separating milk fat into fractions that vary in melting properties can add 15 value to the milk fat. When such fractions are combined with custom blending and texturization technologies, a range of milk fat fraction ingredients with varying functional properties can be produced. The most common method used to fractionate milk fat is dry crystallization, a simple, physical process that separates milk fat into fractions with different 20 physical and chemical properties. The process involves heating anhydrous milk fat (99.9% fat) in a crystallizer (e.g., a stainless steel jacketed tank) until fully melted. The milk fat is then allowed to cool and stirred using controlled conditions until the crystallization process is complete. The result is a slurry consisting of solid milk fat crystals suspended in liquid milk fat. 25 In a final step, the fractions may be separated -- either by vacuum or pressure filtration or centrifugation -- into milk fat ingredients with melting points much lower and higher than milk fat's typical melting point. Fractions with melting points ranging from 43-155 0 F may be obtained in this manner in contrast to the 95-96oF melting point of ordinary butter. While this type of process can change the physical 30 characteristics of butter, it generally does not alter its characteristic flavor. Milk fat fractions can be used to improve the texture of low-fat cheese and increase the spreadability of butter at refrigerated temperatures. The functionality of 14 WO 99/08540 PCT/US98/16829 cold-spreadable butter is a direct result of the functionality of the milk fat ingredients used. The physical characteristics result from the complex interactions between the various phases (solid milk fat, liquid milk fat and aqueous). One approach for making cold-spreadable butter is to add low-melting 5 fractions to cream during the conventional butter churning process. Another approach is to selectively blend milk fat fractions to achieve a desired melting profile, followed by emulsification with other ingredients and appropriate texturization. A ratio of one-part high-melting fraction to three-part low-melting fraction has proved successful at the pilot level. High-melting fractions can also be 10 used in ultra high temperature-recombined creams to help increase creaming stability during storage and in whipped creams to improve physical and stability properties. The following examples are presented to illustrate the present invention and 15 to assist one of ordinary skill in making and using the same. The examples are not intended in any way to otherwise limit the scope of the invention. Example 1 Two Holstein dairy cows were fed a total mixed ration consisting of 50% concentrate, 25% alfalfa haylage (farm-grown), and 25% corn silage (farm-grown) 20 on a dry matter basis as a basal diet for one week to acclimate them to the ration beginning on day 1. The concentrate contained (expressed as percent of dry matter): corn, 58.9; soybean meal (44% CP), 32.6; dicalcium phosphate, 1.5; limestone, 1.75; sodium bicarbonate, 1.5; magnesium oxide, 0.5; trace mineral salt, 1.0; vitamin A, D, E premix (2,000,000 IU of vitamin A, 400,000 IU of vitamin D, 200 IU of 25 vitamin E per pound), 0.2; vitamin E premix (20,000 IU per pound), 0.1. The cows were housed in a free stall facility at the South Dakota State University Dairy Research and Teaching Facility. The cows were fed using Calan feeding doors (American Calan, Inc., Northwood, NH) and amounts fed and refused were recorded daily. Menhaden fish oil (Zapata Protein, Inc., Reedville, VA) was incorporated in 30 the ration gradually beginning on day 9 until cows were offered 454 g of fish oil 15 WO 99/08540 PCT/US98/16829 daily. Fish oil was incorporated in the ration through day 29. Milk production, milk composition, feed intake, and milk fat composition were monitored through 4 weeks. Milk fat composition of samples from the cows fed fish oil was analyzed by packed column gas chromatography (Jones, et al. Quantitative determination of 5 double bond positions in unsaturated fatty acids after oxidative cleavage, J. Amer. Oil Chem. Soc., 42:121 (1965)). Ten ml of each milk sample were placed in individual Mojonnier flasks (Mojonnier, Charleston, SC). An indicator, 1.5 ml of ammonium hydroxide, 10 ml ethanol, 25 ml ethyl ether, and 25 ml of petroleum ether were added to the milk sample followed by centrifugation for one minute. The 10 clear layer was decanted to a flask and the sample was evaporated to dryness on a rotary evaporator. Petroleum ether (approx 3 ml) was added to the flask and the sample was evaporated to dryness again. Boron trifluoride butanol (approximately 3 ml) was added to the sample and the sample was heated for approximately 30 minutes. Samples were allowed to cool while connected to a cold water condensor. 15 Contents of the flask were then transferred to a separatory funnel. Ten ml of distilled water was added followed by 8 ml of saturated sodium bicarbonate solution and 50 ml of half-saturated sodium chloride solution. After allowing the sample to stand for 5 minutes, the bottom layer was discarded. Another 50 ml of half-saturated sodium chloride solution was added and allowed to stand for 5 minutes and again the 20 bottom layer was discarded. This procedure was repeated 3 times. Equal volumes of a portion of the top layer containing the butylated fatty acids and petroleum ether were then transferred to a GC vial for analysis. A sample of fish oil was analyzed by capillary column gas chromatography using the following procedure. A 6 - 20 mg sample of fish oil was added to a 16 X 25 150 mm extraction tube, followed by 50 ml of a solution of 0.5% valeric acid and 1.0% 10-undecanoic acid in n-butanol as an internal standard. n-Butanol (750 ml) was added to the sample and vortexed for 4 - 5 seconds. While vortexing, 75 ml of acetyl chloride were slowly added to the sample. Samples were gassed with N 2 , sealed, and heated at 1000 C for 1.5 h. After cooling, 5 ml of 6% K 2
CO
3 was added 30 to the sample followed by addition of 1 ml hexane. The sample was vortexed for 0.5 min, then centrifuged at 250 x g for 20 min. The lower layer was aspirated and the top layer was washed 3 times with distilled, deionized water. The upper layer was 16 WO 99/08540 PCT/US98/16829 transferred to a GC vial and analyzed using a Hewlett Packard 6890 series gas chromatograph. Individual fatty acids were identified using known standards (Table 1). Results 5 Table 2 shows the average milk production and composition of milk from the cows fed 454 g of fish oil daily for 14 days. Milk samples were obtained prior to beginning fish oil supplementation for the pretreatment values. Fish oil in the ration was increased gradually for 1 week, then cows were fed at 454 g of fish oil daily through week 1 and week 2. Milk samples were obtained at the end of week 1 and 10 week 2. Table 2 Milk production and composition of milk from cows fed 454 g of fish oil daily for 14 days Milk Production (kg/day) Milk Composition (wt.%) Fat Protein Lactose SNF Pretreatment 27.6 4.72 3.52 4.75 8.91 Week 1 27.6 3.90 3.33 4.74 8.70 Week 2 29.1 3.39 3.38 4.91 8.95 15 Tank milk from the South Dakota State University Dairy Farm was used as a comparison for pretreatment and treatment milk samples. The tank milk was from a herd of cows fed a diet containing the ingredients listed in Table 3. Pretreatment milk samples were obtained from the cows to be fed the fish oil supplemented diet 20 prior to initiation of daily supplementation with 454 gm of Menhaden fish oil. Treatment milk samples were obtained after cows had been receiving 454 gm of Menhaden fish oil daily for 14 days. Samples were analyzed using a butyl esterification method of gas chromatography using a Varian model 3700. Table 4 shows the fatty acid compositions (mg/g of fat) of the tank milk and milk produced 25 by cows before and after supplementation of their feed with 454 gm (1.0 lb) by dry weight fish oil per cow. 17 WO 99/08540 PCT/US98/16829 Table 3 Contents of Basic Diet Fed to Herd From Which Tank Milk Obtained Ingredient Amount (%) Corn, shelled rolled 54.80 Barley, rolled 9.20 Soybean meal, 44% CP 27.65 Molasses, liquid 5.00 Dicalcium phosphate 1.25 Sodium bicarbonate 0.80 Trace mineral salt 0.50 Magnesium oxide 0.25 Limestone 0.25 Vitamin A, D, & E premix 0.20 Vitamin E premix 2 0.10 5 'Contains 2,000,000 IU of vitamin A, 400,000 IU of vitamin D, and 200 IU of vitamin E per pound. 2 Contains 20,000 IU of vitamin E per pound. 10 Discussion Inclusion of Menhaden fish oil in diets fed to dairy cows provided long-chain fatty acids that resulted in alterations in milk fat composition. In general, the percent of saturated fatty acids decreased from approximately 71% pretreatment to 61% 15 during treatment with a concurrent increase in unsaturated fatty acids from approximately 27% to 36%. Saturated fats have been implicated as a risk factor in generation of heart disease, therefore health care officials have recommended a shift from saturated fatty acids to unsaturated fatty acids. Feeding fish oil to dairy cows results in decreased percentages of saturated fatty acids in milk fat thereby providing 20 a healthier product for human consumption. Feeding Menhaden fish oil to dairy cows also resulted in an increase in the concentration of CLA in milk fat. Average pretreatment values (see Table 4) for CLA were 3.1 mg/g of fat compared to 27.2 mg CLA/g of fat in samples from cows fed the fish oil supplemented diet. The increase in CLA varied between animals 25 from 23 mg/g of fat to 31.3 mg/g of fat. 18 WO 99/08540 PCT/US98/16829 Example 2 Two cows in late lactation were fed a ration containing fish oil (Table 5) and two other cows in late lactation were fed a ration containing fish meal (Table 6). 5 Table 5 Fish Oil Grain Mix Ingredient Percent Amount (lbs) Corn, rolled 71.4 714.0 Soybean meal, 44% CP 20.0 200.0 Fish Oil 4.0 40.0 Dicalcium phosphate 1.2 12.0 Trace mineral salt 1.0 10.0 Magnesium oxide 0.5 5.0 Limestone 1.6 16.0 Vitamin A, D, & E 0.2 2.0 premix Vitamin E premix 0.1 1.0 Table 6 10 Fish Meal Grain Mix Ingredient Percent Amount (lbs) Corn, rolled 81.0 810.0 Soybean meal, 44% CP 8.5 85.0 Menhaden Fish Meal 7.2 72.0 Dicalcium phosphate 1.0 10.0 Trace mineral salt 1.0 10.0 Magnesium oxide 0.5 5.0 Limestone 0.5 5.0 Vitamin A, D, & E 0.2 2.0 premix Vitamin E premix 0.1 1.0 The total mixed ration (dry matter basis) consisted of: 1) 50% respective grain mix (see Tables 5 and 6); 15 2) 25% corn silage; 3) 25% alfalfa hay. The diet was fed individually to cows, ad libitum, with amounts offered and refused recorded daily. Cows were fed the normal herd ration on days 1 through 3. 19 WO 99/08540 PCT/US98/16829 Concentrate containing fish oil or fish meal was added to rations in increasing amounts beginning on day 4 with full allotments beginning on day 10. Milk samples (a.m. and p.m.) were composited for analysis of milk composition (fat %, protein %, lactose %, solids, and somatic cell count) and milk 5 fat composition by gas chromatography. Milk weights are recorded for each milking. Milk samples were obtained on day 3 prior to initiation of feeding fish oil, on days 7 and 10 after starting incorporation of fish oil (fish meal), and on day 14 after cows were receiving full allotments of fish oil (fish meal). Samples were analyzed for fatty acid composition using a butyl esterification method by gas 10 chromatography (Hewlett-Packard model 6890). The results are shown in Tables 7 9. In addition to decreased percentages of saturated fatty acids in milk fat, supplementing the feed of dairy cows with fish oil resulted in an increase in the concentration of CLA in milk fat (see Table 7). Average pretreatment values (see 15 day 3 in Table 7) for CLA were 4.3 mg/g of fat compared to 24.7-27.0 mg CLA/g of fat in samples from cows fed the full allotment of fish oil supplemented diet. The total omega-3 content of the milk produced increased to as high as 11.6 mg/g of fat in contrast to a pretreatment level of 6.3 mg/g of fat. The levels of transvacceniic acid and petroselinic acid also increased in the milk produced by the cows fed the 20 full allotment of fish oil supplemented diet (to 61.1-68.8 mg/g of fat and 10.1-12.1 mg/g of fat respectively). Supplementing the feed of dairy cows with fish meal also resulted in an increase in the concentration of CLA in milk fat (see Table 8). Average pretreatment values (see day 3 in Table 8) for CLA were 4.7 mg/g of fat compared to 25 5.8-9.5 mg CLA/g of fat in samples from cows fed the full allotment of fish meal supplemented diet (days 10 and 14). The total omega-3 content of the milk produced was increased up to about 8.3 mg/g of fat in contrast to a pretreatment level of 6.4 mg/g of fat. To confirm the presence of c9.tl l/t9.cl 1 CLA, one of the milk samples from 30 day 14 of the fish oil supplemented feeding trials was examined by an independent laboratory. The analysis was carried out by gas chromatography on duplicate runs of material which had been hydrolysed and esterified to produce fatty acid methyl 20 WO 99/08540 PCT/US98/16829 esters (Ha et al., J. Agric. Food Chem., 37:75 (1989)). This analysis determined the CLA content to be 2.8-2.9 wt.% of the total milk fat but was unable to establish between whether the CLA was present as the c9.tl 1 or t9.cl 1 isomer. By spiking a sample with standard compounds, it was established that the t9.tl 1 or tl0.tl2 CLA 5 isomers were not present in the milk samples. Throughout this application various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. 10 The invention has been described with reference to various specific and illustrative embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. 21 WO 99/08540 PCT/US98/16829 Table 1 Typical Fish Oil Fatty Acid Composition Fatty Acid Generic (mg/g) Menhaden (mg/g) C4:0-C12:0 0 0 C14:0 73.4 117.5 C14:1 0 0 C16:0 158.9 146.2 C16:1 77.0 128.9 C18:0 32.5 26.4 C18:1 isomers petroselaidic 14.2 11.7 elaidic 1.4 0 petroselinic 1.2 0 transvaccenic 0 0 oleic 90.8 90.0 vaccenic 29.2 34.2 linoelaidic (18:2trans) 1.0 1.0 linoleic (18:2cis) 12.0 9.0 y lineolenic (18:3) 2.1 4.0 a linolenic (18:3) 8.6 5.4 CLA 1.6 3.2 C20:1 3.3 2.6 C20:4 13.6 5.4 C20:5 180.7 176.1 C24:1 7.1 7.4 C22:5 23.0 28.0 C22:6 118.4 58.4 22 WO 99/08540 PCT/US98/16829 Table 4 Fatty acid composition (mg/g of fat) of tank milk, pretreatment milk, and posttreatment milk Fatty Acid Tank Milk Pretreatment Treated C 4:0 39.6 38.9 42.1 C 6:0 25.8 25.6 23.7 C 8:0 15.6 15.6 13.0 C10:0 36.6 37.4 28.2 C12:0 43.5 45.4 32.8 C14:0 117.5 125.5 118.1 C14:1 17.1 17.0 16.7 C15:0 13.9 12.6 10.0 C15:1 03.4 3.5 3.6 C16:0 282.0 321.9 279.8 C16:1 28.6 31.4 39.9 C17:0 8.2 7.3 7.0 C17:1 4.1 3.6 4.1 C18:0 84.5 81.5 52.1 C18:1 216.4 175.9 196.8 C18:2 22.9 20.9 30.0 C18:3y 1.8 1.9 3.5 C18:30s 6.1 5.7 13.8 CLA 5.0 3.1 27.2 C20:4 8.8 7.3 17.5 C20:5 0.8 0.7 4.3 C22:5 0.5 0.5 2.0 C22:6 0.0 0.0 0.9 Tot. Omega-3 (mg/g) 6.9 6.4 21.0 Saturated (%) 66.7 71.2 60.7 Unsaturated (%) 31.6 27.2 36.0 Polyunsat'd(%) 5.8 5.1 9.9 Unidentified (%) 1.7 1.7 3.3 23 WO 99/08540 PCT/US98/16829 Table 7 Fatty acid composition (mg/g of fat) of milk from cows fed fish oil Fatty Acid Day3 Day7 Day 10 Day 14 C 4:0 29.3 29.4 28.2 29.6 C 6:0 18.4 18.4 19.7 18.6 C 8:0 11.2 11.0 12.8 11.6 C10:0 24.7 24.1 29.9 25.6 C12:0 29.2 28.2 36.4 31.0 C14:0 93.2 97.7 113.4 113.3 C14:1 8.8 8.5 14.4 15.5 C15:0 10.4 10.5 11.3 12.3 C15:1 4.4 4.0 3.6 1.8 C16:0 262.0 271.8 272.1 257.3 C16:1 11.9 12.4 20.9 24.5 C17:0 4.4 4.1 4.2 4.6 C17:1 5.9 6.1 5.8 6.2 C18:0 139.6 129.1 58.0 56.1 C18:1 Petroselaidic 3.3 4.7 7.1 6.9 C18:1 Elaidic 3.7 4.6 7.5 8.3 C18:1 Petroselinic 6.8 8.1 12.1 10.1 C18:1 Transvaccenic 12.7 20.6 68.8 61.1 C18:1 Oleic 221.7 196.6 143.1 143.0 C18:2 36.7 34.5 33.6 26.1 C18:3y 1.9 3.5 2.2 2.6 C18:3a 6.3 7.0 6.5 8.1 CLA 4.3 6.9 27.0 24.7 C20:3 0 0 0 2.2 C20:4 2.4 2.3 2.9 2.8 C20:5 0 0 0 2.1 C22:5 0 0 0 1.4 C22:6 0 0 0 0 Tot. Omega-3 (mg/g) 6.3 7.0 6.5 11.6 Saturated (%) 65.0 65.2 61.2 58.5 Unsaturated (%) 35.0 34.0 37.8 36.6 Polyunsaturated (%) 5.4 5.7 7.5 7.3 Unidentified (%) 4.3 5.1 5.2 8.8 24 WO 99/08540 PCT/US98/16829 Table 8 Fatty acid composition (mg/g of fat) of milk from cows fed fish meal Fatty Acid Day3 Day 7 Day 10 Day 14 C 4:0 30.5 32.0 33.3 32.6 C 6:0 15.2 20.6 21.3 20.7 C 8:0 11.2 12.6 12.8 12.6 C10:0 24.1 26.6 27.3 26.5 C12:0 27.8 30.0 31.8 31.1 C14:0 92.6 97.1 101.1 100.8 C14:1 6.9 9.2 9.9 11.7 C15:0 10.3 10.0 10.6 11.9 C15:1 3.8 3.6 4.2 4.0 C16:0 266.2 273.1 276.9 266.6 C16:1 11.7 15.3 16.4 19.7 C17:0 4.7 4.3 4.5 4.7 C17:1 5.9 5.3 5.7 5.8 C18:0 144.0 122.5 114.9 105.4 C18:1 Petroselaidic 3.0 3.2 2.7 2.9 C18:1 Elaidic 3.4 3.4 1.7 3.5 C18:1 Petroselinic 6.8 6.8 5.8 5.4 C18:1 Transvaccenic 13.1 14.2 13.5 14.3 C18:1 Oleic 220.6 215.5 215.1 218.1 C18:2 32.6 34.8 30.5 24.3 C18:3y 2.0 2.4 3.1 3.8 C18:300 6.4 6.0 6.6 8.3 CLA 4.7 5.7 5.8 9.5 C20:3 0 .6 .7 0 C20:4 2.2 2.3 2.4 2.2 C20:5 0 0 0 0 C22:5 0 0 0 0 C22:6 0 0 0 0 Tot. Omega-3 (mg/g) 6.4 6.0 6.6 8.3 Saturated (%) 65.5 65.7 66.3 64.0 Unsaturated (%) 34.5 35.1 34.7 35.8 Polyunsaturated (%) 5.3 5.7 5.5 5.5 Unidentified (%) 4.3 3.5 3.3 4.4 25 WO 99/08540 PCT/US98/16829 kn .. c. 00 ! ! !0! N m6 oon 4n ~.u Cooo "CIS ro o -oCoo oc .I as -N~ C C_ - 26 NCIA 00 Li'-o "7tI 263 Cd -C U b ot N + C O N j 4 0 C 26 -I
Claims (1)
- What is claimed is:1 ) A dairy product derived from raw milk produced by a ruminant fed a diet comprising fish oil, said raw milk comprising at least about 15 mg CLA per gram of fat.2) The dairy product of claim 1 wherein the ruminant is fed a diet comprising at least about 0.25 %> by dry weight of the fish oil.3) The dairy product of claim 2 wherein the ruminant is fed a diet comprising about 1 %> to about 4 %> by dry weight of the fish oil.4) The dairy product of claim 2 wherein the ruminant is fed the diet for at least two days.5) The dairy product of claim 1 wherein the ruminant is a cow, deer, sheep, buffalo, or goat.6) The dairy product of claim 1 wherein said dairy product is milk, cheese, yogurt, butter, ice cream, buttermilk, sour cream, ghee, sherbert, anhydrous butter oil, anhydrous butter fat, powdered milk, condensed milk, evaporated milk, whey products, half & half, or cream.7) The dairy product of claim 1 wherein said dairy product has a fat content of at least about 10 wt.%>.8) The dairy product of claim 1 wherein the fish oil comprises Menhaden fish oil, cod liver oil, mackerel oil, salmon oil, catfish oil, herring oil, or a mixture thereof. ) The dairy product of claim 1 wherein the raw milk comprises at least about 20 mg CLA per gram of fat.10) The dairy product of claim 1 wherein the raw milk further comprises at least about 10 mg omega-3 fatty acid per gram of fat.11) The dairy product of claim 1 wherein said raw milk comprises a fat fraction having a fatty acid composition comprising at least about 25 mg/g transvaccennic acid.12) The dairy product of claim 1 wherein said raw milk comprises a fat fraction having a fatty acid composition comprising at least about 8 mg/g petroselinic acid.13) The dairy product of claim 1 wherein said raw milk comprises a fat fraction having a fatty acid composition comprising at least about 2.0 mg/g C20:5 fatty acid.14) The dairy product of claim 1 wherein the fatty acid composition further comprises at least about 8 mg/g α-linolenic acid.15) Raw milk comprising a fat fraction having a fatty acid composition including at least about 15 mg/g CLA and at least about 10 mg/g omega-3 fatty acid.16) The milk of claim 15 wherein the fatty acid composition further comprises at least about 25 mg/g transvaccennic acid and at least about 8 mg/g petroselinic acid.17) A lipid composition derived from raw milk, wherein said raw milk comprises a fat fraction having a fatty acid composition including at least about 15 mg/g CLA and at least about 10 mg/g omega-3 fatty acid. 18) The lipid composition of claim 17 wherein the fatty acid composition further comprises at least about 25 mg/g transvaccennic acid and at least about 10 mg/g petroselinic acid.19) The lipid composition of claim 17 wherein said lipid composition is a low- melting milk fat fraction.20) A fatty acid composition derived from raw milk comprising a fat fraction having a fatty acid composition including at least about 15 mg/g CLA and at least about 10 mg/g omega-3 fatty acid.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5567597P | 1997-08-18 | 1997-08-18 | |
| US60/055675 | 1997-08-18 | ||
| US99244097A | 1997-12-17 | 1997-12-17 | |
| US08/992440 | 1997-12-17 | ||
| PCT/US1998/016829 WO1999008540A1 (en) | 1997-08-18 | 1998-08-13 | Dairy products with enhanced cla content |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8828798A true AU8828798A (en) | 1999-03-08 |
| AU728842B2 AU728842B2 (en) | 2001-01-18 |
Family
ID=26734514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU88287/98A Ceased AU728842B2 (en) | 1997-08-18 | 1998-08-13 | Dairy products with enhanced CLA content |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1005277A4 (en) |
| AU (1) | AU728842B2 (en) |
| NZ (1) | NZ503398A (en) |
| WO (1) | WO1999008540A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110292113A (en) * | 2018-03-21 | 2019-10-01 | 味全食品工业股份有限公司 | Milk and dairy products secreted by ruminants |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956400B4 (en) * | 1999-11-24 | 2005-09-08 | Sagredos, Angelos, Prof. Dr. | Therapeutically active composition, a process for its preparation and its use |
| DE50108392D1 (en) * | 2000-05-05 | 2006-01-19 | Fresenius Kabi De Gmbh | COMBINATION PREPARATION OF OVA-3-FATTY ACIDS AND CONJUGATED LINOLIC ACIDS FOR THE TREATMENT OF IMMUNOLOGICALLY PRESENTED PATTERNS |
| DE60142925D1 (en) | 2000-12-22 | 2010-10-07 | Univ Catholique Louvain | METHOD OF MODIFYING THE ISOMIC TRANS FATTY ACID PROFILE IN CRAB AND MILK AND INCREASING THE CONCENTRATION OF CIS-9, TRANS-11 CONJUGATED LINOLEIC ACID |
| GB0105622D0 (en) | 2001-03-07 | 2001-04-25 | Natural Asa | Compositions |
| NZ555756A (en) | 2004-12-15 | 2008-07-31 | O & T Farms | Preparation and use of high omega-3 and omega-6 feed |
| CA2702577A1 (en) | 2007-10-15 | 2009-04-23 | Jbs United, Inc. | Method for increasing performance of offspring |
| CN108064950A (en) * | 2016-11-15 | 2018-05-25 | 内蒙古伊利实业集团股份有限公司 | A kind of liquid diary product with protection cardiovascular effect and preparation method thereof |
| WO2018109203A2 (en) * | 2016-12-15 | 2018-06-21 | Frieslandcampina Nederland B.V. | Two-dimensional fractionation of milk fat |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770247A (en) * | 1996-10-03 | 1998-06-23 | Wisconsin Alumni Research Foundation | Method of increasing the CLA content of cow's milK |
-
1998
- 1998-08-13 AU AU88287/98A patent/AU728842B2/en not_active Ceased
- 1998-08-13 NZ NZ503398A patent/NZ503398A/en unknown
- 1998-08-13 WO PCT/US1998/016829 patent/WO1999008540A1/en not_active Ceased
- 1998-08-13 EP EP98939938A patent/EP1005277A4/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110292113A (en) * | 2018-03-21 | 2019-10-01 | 味全食品工业股份有限公司 | Milk and dairy products secreted by ruminants |
Also Published As
| Publication number | Publication date |
|---|---|
| AU728842B2 (en) | 2001-01-18 |
| NZ503398A (en) | 2002-06-28 |
| WO1999008540A1 (en) | 1999-02-25 |
| EP1005277A4 (en) | 2001-08-29 |
| EP1005277A1 (en) | 2000-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bauman et al. | Production of butter with enhanced conjugated linoleic acid for use in biomedical studies with animal models | |
| Djordjevic et al. | Fatty acid profile of milk | |
| Chilliard et al. | A review of nutritional and physiological factors affecting goat milk lipid synthesis and lipolysis | |
| AU2001273028B2 (en) | Improved methods of incorporating polyunsaturated fatty acids in milk | |
| Enjalbert et al. | Effects of duodenal infusions of palmitic, stearic, or oleic acids on milk composition and physical properties of butter | |
| US20030175403A1 (en) | Potentiated bioactive additives and method of use | |
| AU2001273028A1 (en) | Improved methods of incorporating polyunsaturated fatty acids in milk | |
| Abu-Ghazaleh et al. | Conjugated linoleic acid and other beneficial fatty acids in milk fat from cows fed soybean meal, fish meal, or both | |
| Nudda et al. | Relationships between the contents of vaccenic acid, CLA and n− 3 fatty acids of goat milk and the muscle of their suckling kids | |
| La Terra et al. | Increasing pasture intakes enhances polyunsaturated fatty acids and lipophilic antioxidants in plasma and milk of dairy cows fed total mix ration | |
| JP3614859B2 (en) | Nervonic acid composition | |
| AU728842B2 (en) | Dairy products with enhanced CLA content | |
| Moallem et al. | Transfer rate of α-linolenic acid from abomasally infused flaxseed oil into milk fat and the effects on milk fatty acid composition in dairy cows | |
| EP2037757B1 (en) | Feed product for dairy cows and method of obtaining a dairy product | |
| Sharma et al. | Role of omega-3 fatty acids, conjugated linoleic acid and phytosterols in improving functionality of dairy products | |
| Bianchi et al. | Addition of palm oil in diet of dairy ewes reduces saturates fatty acid and increases unsaturated fatty acids in Milk | |
| AU2020249431B2 (en) | Bovine milk having a high n6-polyunsaturated fatty acid content | |
| Abbas et al. | MILK BIOACTIVE LIPIDS AS POTENTIAL HEALTHY FRACTIONS: A REVIEW | |
| Nudda et al. | The use linseed and cottonseed to change the milk fatty acid profile in early lactation dairy goats | |
| WO2005036981A1 (en) | Method for enriching nervonic acid in expressed milk of ruminants | |
| Sharma et al. | Ghee: Fatty Acids, Triacylglycerols, and Phospholipids | |
| Sharma et al. | Fatty Acids, Triacylglycerols, and Phospholipids | |
| Adeyeye | Lipid composition of three different types of land snails consumed in Nigeria | |
| HK40113628A (en) | Bovine milk having a high n6-polyunsaturated fatty acid content | |
| Mierliță et al. | The influence of by-pass fats used in ewes' diet on the productive performances and on the fatty acids profile from milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |